



Baishideng Publishing Group

Copyright assignment

Name of Journal: *World Journal of Hepatology*

ESPS Manuscript NO: 28585

Title: **Phase 3 trial of first generation protease inhibitor therapy for HCV/HIV coinfection**

Authors List: Kenneth E. Sherman, Minhee Kang, Richard Sterling, Triin Umbleja, Kristen Marks, Jennifer J. Kiser, Beverly Alston-Smith, Wayne Greaves, Adeel A. Butt

Correspondence To: Kenneth E. Sherman

Application for copyright transfer will be made by written declaration of and attestation to the following:

- 1 That the manuscript is not simultaneously being considered by other journals or is already published elsewhere.
- 2 That the manuscript has no redundancy, plagiarism, data fabrication, or falsification.
- 3 That the author(s) has (have) no conflict of interest related to the manuscript.
- 4 That all experiments involving animals and human subjects were designed and performed in compliance with the relevant laws regarding the humane care and use of subjects.
- 5 That the material contained within the manuscript is original, with all information from other sources appropriately referenced, and that written specific permission has been granted by any existing copyright holders prior to publication and is clearly cited and available.
- 6 That the author(s) agree to transfer to Baishideng Publishing Group Inc exclusive copyright ownership for all formats of the manuscript, including print and electronic formats, English and non-English language formats, and subsequent editions such as Erratum, in addition to all rights for (1) granting permission to republish or reprint the materials in whole or in part, with or without a fee, (2) printing copies for free distribution or for sale, and (3) republishing the materials in a compendium or in any other format.

7 That the author(s) acknowledge that all articles published by Baishideng Publishing Group Inc are selected by an in-house editor and fully peer-reviewed by external reviewers. Baishideng Publishing Group Inc applies the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

8 That the author(s) agree to publish the related documents (e.g. peer review report, answers to reviewers, CrossCheck report, signed copyright assignment,*etc.*) of the manuscripts at the same time that the manuscript is published online.

9 That there are no errors in grammar, syntax, spelling, punctuation, or logic.

10 That all figures and tables have been correctly placed and clearly identified, and meet the journal's standards of high-resolution quality.

11 That the references are numbered according to their order of appearance in the main text of the manuscript.

This declaration must be signed by all authors, individually and in his/her own handwriting, following the order of the authors' names appearing on the title page of the manuscript.

Note: Each manuscript published in the *World Series* journals is allowed only one first author and only one corresponding author. Designation of co-first authors and co-corresponding authors is not permitted.

A gentle reminder: The Baishideng Publishing Group Inc reminds all authors that instances of (1) plagiarism; (2) data fabrication and/or falsification; (3) redundant publication; and/or (4) misrepresentation about the qualifications for authorship are the responsibility of every author listed on a paper, *regardless of their intent or knowledge*. If an author suspects or is aware of any of these irregularities in their manuscript, it is strongly recommended that the authors immediately contact the journal and initiate withdrawal of the submission. Once a manuscript has been published online, withdrawal (retraction) of the paper due to the irregularities listed above will incur a charge of USD10,000.00 to compensate the publisher for the loss incurred. The online format of the manuscript will be withdrawn within four weeks of the request.


The following should be noted when all authors sign the agreement:

1 Authors are prohibited from making any changes to the BAISHIDENG PUBLISHING GROUP INC COPYRIGHT ASSIGNMENT without the prior consent of the editorial board. If authors have any different opinion about the copyright transfer agreement, they should contact the editorial office before making any changes to it.

2 All authors will sign their names on a single page, in the order that they appear on the title page of the manuscript; multiple signature pages are not acceptable. After all authors have signed, please return the signed version (in PDF format) to the editorial office. Delivery of a printed version of the copyright transfer agreement or faxing the copyright transfer agreement is not acceptable. This agreement will be released online together with the published article.

3 Each author must sign his/her name and date himself/herself. Others are not allowed to sign the agreement on behalf of authors. If this situation is found to have occurred, the manuscript will be withdrawn immediately, all of the authors will be placed onto a publication blacklist for any journal published by the Baishideng Publishing Group Inc, and any submissions to journals published by the Baishideng Publishing Group Inc will not be considered or accepted for publication.

Name: Kenneth E. Sherman

Signature:  Date: 9/20/16

Name: Minhee Kang

Signature:  Date: 9/20/2016


Name: Richard Sterling

Signature:  Date: 9/23/16

Name: Triin Umbleja

Signature:  Date: 9/20/2016

Name: Kristen Marks

Signature:  Date: 10/4/16

Name: Jennifer J. Kiser

Signature:  Date: 10/4/16

Name: Beverly Alston-Smith

Signature: NIH agreement attached Date: 10-6-2016

Name: Wayne Greaves

Signature:  Date: 10/7/2016

Name: Adeel A. Butt

Signature:  Date: 11 October 2016

NIH Publishing Agreement & Manuscript Cover Sheet

By signing this Cover Sheet, the Author, on behalf of NIH, agrees to the provisions set out below, which **modify and supersede**, solely with respect to NIH, any conflicting provisions that are in the Publisher's standard copyright agreement (the "Publisher's Agreement"). If a Publisher's Agreement is attached, execution of this Cover Sheet constitutes an execution of the Publisher's Agreement, subject to the provisions and conditions of this Cover Sheet.

1. **Indemnification.** No Indemnification or "hold harmless" obligation is provided by either party.
2. **Governing Law.** This agreement will be governed by the law of the court in which a claim is brought.
3. **Copyright.** Author's contribution to the Work was done as part of the Author's official duties as a NIH employee and is a Work of the United States Government. Therefore, copyright may not be established in the United States. 17 U.S.C. § 105. If Publisher intends to disseminate the Work outside of the U.S., Publisher may secure copyright to the extent authorized under the domestic laws of the relevant country, subject to a paid-up, nonexclusive, irrevocable worldwide license to the United States in such copyrighted work to reproduce, prepare derivative works, distribute copies to the public and perform publicly and display publicly the work, and to permit others to do so.
4. **No Compensation.** No royalty income or other compensation may be accepted for work done as part of official duties. The author may accept for the agency a limited number of reprints or copies of the publication.
5. **NIH Representations.** NIH represents to the Publisher that the Author is the sole author of the Author's contribution to the Work and that NIH is the owner of the rights that are the subject of this agreement; that the Work is an original work and has not previously been published in any form anywhere in the world; that to the best of NIH's knowledge the Work is not a violation of any existing copyright, moral right, database right, or of any right of privacy or other intellectual property, personal, proprietary or statutory right; that where the Author is responsible for obtaining permissions or assisting the Publishers in obtaining permissions for the use of third party material, all relevant permissions and information have been secured; and that the Work contains nothing misleading, obscene, libelous or defamatory or otherwise unlawful. NIH agrees to reasonable instructions or requirements regarding submission procedures or author communications, and reasonable ethics or conflict of interest disclosure requirements unless they conflict with the provisions of this Cover Sheet.
6. **Disclaimer.** NIH and the Author expressly disclaim any obligation in Publisher's Agreement that is not consistent with the Author's official duties or the NIH mission, described at <http://www.nih.gov/about/>. NIH and the Author do not disclaim obligations to comply with a Publisher's conflict of interest policy so long as, and to the extent that, such policy is consistent with NIH's own conflict of interest policies.
7. **For Peer-Reviewed Papers to be Submitted to PubMed Central.** The Author is a US government employee who must comply with the NIH Public Access Policy, and the Author or NIH will deposit, or have deposited, in NIH's PubMed Central archive, an electronic version of the final, peer-reviewed manuscript upon acceptance for publication, to be made publicly available no later than 12 months after the official date of publication. The Author and NIH agree (notwithstanding Paragraph 3 above) to follow the manuscript deposition procedures (including the relevant embargo period, if any) of the publisher so long as they are consistent with the NIH Public Access Policy.
8. **Modifications.** PubMed Central may tag or modify the work consistent with its customary practices and with the meaning and integrity of the underlying work.

The NIH Deputy Director for Intramural Research, Michael Gottesman, M.D., approves this publishing agreement and maintains a single, signed copy of this text for all works published by NIH employees, and contractors and trainees who are working at the NIH. No additional signature from Dr. Gottesman is needed.

Author's name: Beverly Alston-Smith

Author's Institute or Center: NIAID/NIH Check if Publisher's Agreement is attached

Name of manuscript/work: Phase 3 trial of first generation protease inhibitor therapy in HCV/HIV coinfection

Name of publication: World Journal of Hepatology



Author's signature

10/06/2016
Date